Attempting to gather evidence of PARP1 relevance in the landscape of BCR::ABL1 p190+ tumors in the clinical practice, a cohort of 60 patient samples, including both ALL and CML patients, all of which were quantified and attested as positive for the BCR::ABL1 p190 isoform, had their PARP1 expression measured through qPCR. This evidence concerns the gene PARP1 and chronic myelogenous leukemia, BCR-ABL1 positive.